Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses

John T. Roehrig, Joachim Hombach, Alan Barrett

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Through the Advisory Committee on Dengue and other Flavivirus Vaccines, the World Health Organization (WHO) has had a long-standing commitment to facilitate and to guide research and development of vaccines for medically important flaviviruses. Recently, the Paediatric Dengue Vaccine Initiative (PDVI) was formed to accelerate the development, testing, and introduction of dengue (DEN) vaccines worldwide, partnering with WHO in this important public health effort. There are now a variety of DEN vaccines in various stages of the developmental pipeline. In an attempt to make interlaboratory information more directly comparable, WHO with the support of PDVI initiated a program to coordinate the procedures used for the plaque-reduction neutralization test (PRNT). The PRNT is the most common assay used to measure neutralizing antibody. The presence of antibody is believed to be most relevant means of determining protective anti-DEN virus (DENV) immunity. While other neutralizing antibody assays are being considered for use in large-scale vaccine field trials, the PRNT is still considered to be the laboratory standard against which other neutralizing antibody as says should be compared. The need for PRNT coordination has been identified at several consultations between the WHO and PDVI. A more complete version of these guidelines is available on the WHO website: http://www.who.int/immunization/documents/date/en/index.html.

Original languageEnglish (US)
Pages (from-to)123-132
Number of pages10
JournalViral Immunology
Volume21
Issue number2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Dengue Vaccines
Dengue Virus
Neutralization Tests
Guidelines
Neutralizing Antibodies
Antibodies
Flavivirus
Vaccines
Pediatrics
Dengue
Advisory Committees
Immunity
Immunization
Referral and Consultation
Public Health
Research

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. / Roehrig, John T.; Hombach, Joachim; Barrett, Alan.

In: Viral Immunology, Vol. 21, No. 2, 01.06.2008, p. 123-132.

Research output: Contribution to journalArticle

@article{e909d8f566f3421e90bda1f847f6a20c,
title = "Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses",
abstract = "Through the Advisory Committee on Dengue and other Flavivirus Vaccines, the World Health Organization (WHO) has had a long-standing commitment to facilitate and to guide research and development of vaccines for medically important flaviviruses. Recently, the Paediatric Dengue Vaccine Initiative (PDVI) was formed to accelerate the development, testing, and introduction of dengue (DEN) vaccines worldwide, partnering with WHO in this important public health effort. There are now a variety of DEN vaccines in various stages of the developmental pipeline. In an attempt to make interlaboratory information more directly comparable, WHO with the support of PDVI initiated a program to coordinate the procedures used for the plaque-reduction neutralization test (PRNT). The PRNT is the most common assay used to measure neutralizing antibody. The presence of antibody is believed to be most relevant means of determining protective anti-DEN virus (DENV) immunity. While other neutralizing antibody assays are being considered for use in large-scale vaccine field trials, the PRNT is still considered to be the laboratory standard against which other neutralizing antibody as says should be compared. The need for PRNT coordination has been identified at several consultations between the WHO and PDVI. A more complete version of these guidelines is available on the WHO website: http://www.who.int/immunization/documents/date/en/index.html.",
author = "Roehrig, {John T.} and Joachim Hombach and Alan Barrett",
year = "2008",
month = "6",
day = "1",
doi = "10.1089/vim.2008.0007",
language = "English (US)",
volume = "21",
pages = "123--132",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses

AU - Roehrig, John T.

AU - Hombach, Joachim

AU - Barrett, Alan

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Through the Advisory Committee on Dengue and other Flavivirus Vaccines, the World Health Organization (WHO) has had a long-standing commitment to facilitate and to guide research and development of vaccines for medically important flaviviruses. Recently, the Paediatric Dengue Vaccine Initiative (PDVI) was formed to accelerate the development, testing, and introduction of dengue (DEN) vaccines worldwide, partnering with WHO in this important public health effort. There are now a variety of DEN vaccines in various stages of the developmental pipeline. In an attempt to make interlaboratory information more directly comparable, WHO with the support of PDVI initiated a program to coordinate the procedures used for the plaque-reduction neutralization test (PRNT). The PRNT is the most common assay used to measure neutralizing antibody. The presence of antibody is believed to be most relevant means of determining protective anti-DEN virus (DENV) immunity. While other neutralizing antibody assays are being considered for use in large-scale vaccine field trials, the PRNT is still considered to be the laboratory standard against which other neutralizing antibody as says should be compared. The need for PRNT coordination has been identified at several consultations between the WHO and PDVI. A more complete version of these guidelines is available on the WHO website: http://www.who.int/immunization/documents/date/en/index.html.

AB - Through the Advisory Committee on Dengue and other Flavivirus Vaccines, the World Health Organization (WHO) has had a long-standing commitment to facilitate and to guide research and development of vaccines for medically important flaviviruses. Recently, the Paediatric Dengue Vaccine Initiative (PDVI) was formed to accelerate the development, testing, and introduction of dengue (DEN) vaccines worldwide, partnering with WHO in this important public health effort. There are now a variety of DEN vaccines in various stages of the developmental pipeline. In an attempt to make interlaboratory information more directly comparable, WHO with the support of PDVI initiated a program to coordinate the procedures used for the plaque-reduction neutralization test (PRNT). The PRNT is the most common assay used to measure neutralizing antibody. The presence of antibody is believed to be most relevant means of determining protective anti-DEN virus (DENV) immunity. While other neutralizing antibody assays are being considered for use in large-scale vaccine field trials, the PRNT is still considered to be the laboratory standard against which other neutralizing antibody as says should be compared. The need for PRNT coordination has been identified at several consultations between the WHO and PDVI. A more complete version of these guidelines is available on the WHO website: http://www.who.int/immunization/documents/date/en/index.html.

UR - http://www.scopus.com/inward/record.url?scp=45749133490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749133490&partnerID=8YFLogxK

U2 - 10.1089/vim.2008.0007

DO - 10.1089/vim.2008.0007

M3 - Article

VL - 21

SP - 123

EP - 132

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 2

ER -